What Researchers Did
Researchers retrospectively evaluated survival outcomes in 24 patients with advanced gastric cancer who received metabolically supported chemotherapy combined with a ketogenic diet, local hyperthermia, and hyperbaric oxygen therapy.
What They Found
Among the patients, 22 (88.0%) achieved a complete response. The mean overall survival was 39.5 months (95% confidence interval: 28.1-51.0), and the mean progression-free survival was 36.5 months (95% confidence interval: 25.7-47.2). No significant problems were reported from the additional therapies.
Canadian Relevance
There is no direct Canadian connection to this study.
Study Limitations
Key limitations include the small sample size of 24 patients and the retrospective, non-comparative study design.